Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...
This article and associated images are based on a poster originally authored by Poppy Wood, James Craswell, Holly Madden, Alicia Galvan-Alvarez, Gabriel Negoita-Giras, David Gibson, Scarlett Turner, ...
A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback